Bio NC
Filter News
Found 17,957 articles
-
Scorpius Holdings Announces Receipt of Filing Delinquency Notification
4/22/2024
Scorpius Holdings, Inc. received an official notice of noncompliance from NYSE Regulation stating that the Company is not in compliance with NYSE American LLC continued listing standards under the timely filing criteria included in Section 1007 of the NYSE American Company Guide due to the failure to timely file the Company’s Form 10-K for the period ended December 31, 2023 by the filing due date of April 16, 2024.
-
BioCryst to Report First Quarter 2024 Financial Results on May 6
4/22/2024
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.
-
Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
4/22/2024
Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced six presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which will be held May 7 to 11, 2024 in Baltimore, MD.
-
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
4/17/2024
Science 37 Holdings, Inc. today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
4/17/2024
BioCryst Pharmaceuticals, Inc. announced that the Brazilian Health Regulatory Agency has granted approval for oral, once-daily ORLADEYO® for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older.
-
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
4/17/2024
G1 Therapeutics, Inc will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET.
-
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
4/17/2024
Milestone ® Pharmaceuticals Inc. today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL.
-
Vast Therapeutics Selected to Present at the American Thoracic Society (ATS) 2024 Respiratory Innovation Summit
4/17/2024
Vast Therapeutics, a clinical-stage life science company focused on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases, today announced an upcoming presentation at the 2024 Respiratory Innovation Summit being held in San Diego May 17-18, 2024.
-
Pelthos Therapeutics Establishes Board of Directors
4/16/2024
Pelthos Therapeutics today announced it has appointed five seasoned industry professionals to serve on its Board of Directors.
-
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
4/16/2024
Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
-
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024
4/16/2024
Chimerix announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock.
-
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
4/16/2024
GeneVentiv Therapeutics, developer of GENV-HEM for all hemophilias, announced it has been awarded a Direct to Phase II Small Business Innovation Research grant for approximately $2,500,000 from the National Heart Lung Blood Institute at the National Institutes of Health.
-
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
4/16/2024
United Therapeutics Corporation today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.
-
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
4/16/2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
-
IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
4/15/2024
IQVIA Holdings Inc. will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024.
-
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
4/15/2024
Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
-
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
4/15/2024
Labcorp announced the availability of the nation's first test for glial fibrillary acidic protein, a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.
-
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer
4/15/2024
KBI Biopharma, Inc. today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.
-
ProPharma Announces Changes to Its Executive Leadership Team
4/11/2024
ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer and Andrew Shaw as General Counsel.
-
Labcorp Declares Quarterly Dividend - April 11, 2024
4/11/2024
Labcorp, a global leader of innovative and comprehensive laboratory services, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.